Novavax (NVAX) Cash & Equivalents Growth (1y) (2011 - 2026)
Novavax (NVAX) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 23.81% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 15.53% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 90.42% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 17.50% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -4.13% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 71.81% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Novavax | 1.23 Bn | 440.77 Mn | 108.82 Mn | 2,038.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,038.03% |
| Dec 31, 2025 | 2.35% |
| Sep 30, 2025 | -53.28% |
| Jun 30, 2025 | 2,319.42% |
| Mar 31, 2025 | -97.78% |
| Dec 31, 2024 | -98.13% |
| Sep 30, 2024 | -11.90% |
| Jun 30, 2024 | -97.93% |
| Mar 31, 2024 | -23.10% |
| Dec 31, 2023 | 5,417.86% |
| Sep 30, 2023 | 5,937.13% |
| Jun 30, 2023 | 4,824.20% |
| Mar 31, 2023 | -60.22% |
| Dec 31, 2022 | -10.33% |
| Sep 30, 2022 | -99.44% |
| Jun 30, 2022 | -99.50% |
| Mar 31, 2022 | 4,789.67% |
| Dec 31, 2021 | -87.76% |
| Sep 30, 2021 | 2,784.41% |
| Jun 30, 2021 | 388.90% |